1. Introduction {#sec1-ijerph-17-00246}
===============

Diabetes mellitus and cancer are complex and growing worldwide health problems, associated with severe acute and chronic complications affecting both the quality of life and survival. According to the International Diabetes Federation, it is estimated that there were 425 million people with diabetes in 2017, and by 2045 the number will rise to 629 million, increasing by 48% \[[@B1-ijerph-17-00246]\]. Whereas cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018, which means that about one in six deaths is due to cancer \[[@B2-ijerph-17-00246]\]. Furthermore, about 8--18% of cancer patients also have diabetes \[[@B3-ijerph-17-00246]\]. Since the incidence of cancer and diabetes is predicted to increase in the following decades, this emphasizes the relevance of adequate prevention, early detection, and appropriate management of both diseases worldwide.

A wide range of epidemiological studies on cancer and diabetes interactions have been conducted and diabetes (primarily T2DM) was shown to be associated with increased risk for some cancer sites (e.g., liver, pancreas, endometrium, colon and rectum, breast, bladder), for other sites there appears to be no association or the evidence is inconclusive \[[@B4-ijerph-17-00246]\]. There are several explanations of the observed associations between T2DM and cancer. First of all, a causal effect of hyperglycaemia, hyperinsulinemia, and inflammation can explain heightened risk of cancer of many sites, in addition to confounding from common risk factors such as adiposity, age, and physical activity. Reverse causality is another potential alternative hypothesis for the associations observed, such as in T2DM and risk of developing hepatocellular and pancreatic cancer, because these cancers can lead to dysfunction of insulin secretion, glucose metabolism, and gluconeogenesis \[[@B4-ijerph-17-00246]\]. Evidence suggests that even when these factors are taken into account, observed associations between cancer and diabetes remain \[[@B5-ijerph-17-00246]\]. Ascertainment bias might also exist since there is heightened medical investigation of diabetic patients, particularly with a new diagnosis of diabetes, but studies have still found significant associations even after the exclusion of the first few years of follow-up after diagnosis \[[@B6-ijerph-17-00246]\]. Additionally, it has been considered that, since T2DM is typically an underdiagnosed disease, and cancer is more frequent in patients with diabetes, the association between these diseases might be undervalued \[[@B4-ijerph-17-00246]\].

Neither diabetes, nor cancer patients can be considered a very homogeneous cohort, with great differences in the disease course, not to mention risk factors, medication for the treatment of the diseases itself and comorbidities, nutritional characteristics, nationality, ethnicity, etc., which may impact the course of diabetes and the risk of cancer and provide a basis for study bias. Therefore, this association of the two diseases remains a question that is relevant now and in years to come.

Most of the previous studies have focused on specific cancer sites. This study provides detailed evaluation of cancer risk by cancer site in the diabetic patient cohort. The aim of this study was to describe the cancer risk pattern among T2DM patients in the whole population of Lithuania.

2. Research Design and Methods {#sec2-ijerph-17-00246}
==============================

2.1. Study Design and Data Source {#sec2dot1-ijerph-17-00246}
---------------------------------

A retrospective cohort study was conducted to examine the relationship between T2DM and site-specific cancer risk. Due to the design of the study, informed consent of individuals was not obtained. The study was approved by the Vilnius Regional Biomedical Research Ethics Committee.

Lithuania has a compulsory health insurance system, therefore, the vast majority of healthcare services are covered by the National Health Insurance Fund (NHIF). NHIF database was created in 1999 for the management, storage, analysis and reporting of the services provided by healthcare organizations. The database includes demographic data and entries on the primary, secondary and tertiary healthcare services provided, hospital admissions, and prescriptions of reimbursed medicine.

The cohort was established by identifying all male and female patients with the first entry of T2DM diagnosis (International Classification of Diseases Australian modification, ICD-10-AM code E11) in the NHIF database from 1 January 2000, until 31 December 2012. To minimize the risk of false type 2 diabetes classification, T2DM status was assigned to patients who were reported as T2DM patients and received prescriptions of antidiabetic medications in the NHIF database.

To ascertain cancer incidence in the cohort, diabetes records were linked to the Lithuanian National Cancer Registry by use of a personal identification number assigned to all Lithuanian citizens, using data up to and including 31 December 2012. The Cancer Registry is a nationwide population-based cancer registry that contains personal and demographic information on all people diagnosed with cancer in Lithuania since 1978. It is a statutory requirement to notify the registry of all cases of malignant neoplasms. All recorded cancers in the Cancer Registry are coded according to the ICD-10-AM.

Patients with T2DM aged 40 years or older were included into the final cohort. We excluded 8230 cases with a cancer diagnosis before the diagnosis of diabetes. The cohort exit date was defined as either the date of death, emigration or 31 December 2012, whichever came first. Overall, 127,290 people (78,823 women and 48,467 men) were included into the study, with the observation period of 828,242.3 person years.

2.2. Statistical Analysis {#sec2dot2-ijerph-17-00246}
-------------------------

We calculated standardized incidence ratios (SIRs) for site-specific and overall cancer as a ratio of observed number of cancer cases in people with T2DM to the expected number of cancer cases in the underlying general Lithuanian population.

Expected number of cancer cases were calculated by multiplication of the exact person-years under observation in the cohort by sex, calendar year, and 5 year age-group specific national incidence rates \[[@B7-ijerph-17-00246]\]. The person-time of observation was computed from the date of the first entry of T2DM diagnosis in the NHIF database until the cohort exit date. 95% confidence intervals for the SIRs were estimated assuming the number of observed cases follows Poisson distribution.

All statistical analyses were carried out using STATA 11 statistical software (StataCorp. 2009. Stata Statistical Software: Release 11.0. College Station, TX, USA). The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Vilnius Regional Biomedical Research Ethics Committee (Nr. 158200-17-913-423).

3. Results {#sec3-ijerph-17-00246}
==========

During 12 years of follow-up, 5959 cases of cancer in men and 6661 cases of cancer in women with T2DM were diagnosed. The study population's baseline characteristics are described in [Table 1](#ijerph-17-00246-t001){ref-type="table"}. Statistically significant increase in risk for overall cancer was observed in women, SIR 1.16 (95% CI 1.14--1.19), but not in men, SIR 1.00 (95% CI 0.98--1.03) ([Table 2](#ijerph-17-00246-t002){ref-type="table"}).

Among males with T2DM, significantly increased risk was found for cancer of the liver (SIR 2.11, 95% CI 1.79--2.49), pancreas (SIR 1.77, 95% CI 1.57--1.99), kidney (SIR 1.46, 95% CI 1.31--1.62), and thyroid (SIR 1.83, 95% CI 1.32--2.54). Colorectal cancer (SIR 1.23, 95% CI 1.14--1.33), skin melanoma (SIR 1.40, 95% CI 1.11--1.76), non--melanoma skin cancer (SIR 1.14, 95% CI 1.05--1.23), male genital organ (SIR 1.86, 95% CI 1.27--2.71), and other endocrine organ (SIR 1.96, 95% CI 1.05--3.64) cancer risk was elevated significantly as well.

For females with T2DM, similarly to males, significantly increased risk was found for cancer of the liver (SIR 1.45, 95% CI 1.17--1.79), pancreas (SIR 1.74, 95% CI 1.56--1.93), kidney (SIR 1.43, 95% CI 1.28--1.60), and thyroid (SIR 1.40, 95% CI 1.22--1.62). Breast (SIR 1.24, 95% CI 1.17--1.31) and corpus uteri (SIR 2.07, 95% CI 1.93--2.21) cancer risk was significantly increased as well.

There was also an inverse association with several cancer sites. A decreased incidence in cancer of the mouth (SIR = 0.49, 95% CI = 0.39-0.62), oesophagus (SIR 0.50, 95% CI 0.37--0.66), larynx (SIR 0.57, 95% CI 0.44-0.73), lung and trachea (SIR 0.53, 95% CI 0.48--0.58) in men, and multiple myeloma (SIR 0.74, 95% CI 0.57-0.96) and leukemia (SIR 0.81, 95% CI 0.68--0.97) in women was observed ([Table 2](#ijerph-17-00246-t002){ref-type="table"}).

4. Discussion {#sec4-ijerph-17-00246}
=============

Results of this large population-based retrospective study based on medical service records and the data of the Cancer Registry showed significant increase in site-specific cancer risk among T2DM patients. We found different risk estimates for overall cancer among males and females. The male vs. female cancer risk difference observed in the patient cohort can be partly explained by an increased number of the most common sex-specific, corpus uteri and breast, cancer in the female cohort group. When these cancers are excluded from the calculation for overall cancer risk, a smaller, yet statistically significant increase for overall cancer in women remains (SIR 1.06, 95% CI 1.03--1.09). Men, on the other hand, had an increased risk for more types of cancer than women, however, these cancers where not so common and did not affect the overall cancer risk.

SIR estimates for overall cancer risk in T2DM patients obtained in our study are comparable to previously performed European cohort studies. A cohort study in Denmark showed a 10% increase in overall cancer for both men and women, with highest risk of hepatic, pancreatic, kidney, and corpus uteri cancer \[[@B8-ijerph-17-00246]\]. A cohort study from Tyrol, Austria revealed a neutral risk for overall cancer, with significant increase in cancer of the pancreas and corpus uteri for women, and cancer of the liver and pancreas for men. \[[@B9-ijerph-17-00246]\]. A recent Finish cohort study showed an 18% higher risk of cancer for diabetic females and 14% for diabetic males, with the liver and pancreas being the sites at highest risk among both sexes \[[@B10-ijerph-17-00246]\].

According to a recent meta-analysis of 121 cohorts (19,239,302 individuals; 1,082,592 events) on all-site cancer risk, the risk of cancer among patients with diabetes is shown to be higher: the pooled adjusted relative risk (RR) for all-site cancer associated with diabetes was 1.27 (95% CI 1.21--1.32) in women and 1.19 (95% CI 1.13--1.25) in men \[[@B11-ijerph-17-00246]\].

With regards to SIR estimates on site-specific cancer incidence, our results are comparable to previous meta-analyses \[[@B12-ijerph-17-00246],[@B13-ijerph-17-00246],[@B14-ijerph-17-00246],[@B15-ijerph-17-00246],[@B16-ijerph-17-00246],[@B17-ijerph-17-00246],[@B18-ijerph-17-00246],[@B19-ijerph-17-00246],[@B20-ijerph-17-00246],[@B21-ijerph-17-00246],[@B22-ijerph-17-00246]\]. We found a twofold rise in liver cancer incidence among men with T2DM and a 45% rise among women with T2DM compared with the general population. These findings have been similar to those observed in the meta-analysis by Wang et al., 2012, where the combined risk estimate for hepatocellular cancer was 2.31 (95% CI 1.87--2.84) among diabetic individuals \[[@B12-ijerph-17-00246]\]. A more recent meta-analysis of cohort studies on T2DM and gender differences in liver cancer by Wang et al., 2016, associated T2DM with an elevated liver cancer incidence in both men (summary RR 2.16, 95% CI 1.74--2.69) and women (summary RR 1.85, 95% CI 1.40--2.44). In addition, the study showed that T2DM and liver cancer association is confounded by smoking and body mass index in both men and women. Results revealed a significantly stronger T2DM and liver cancer association in non-Asian than in Asian women and men \[[@B13-ijerph-17-00246]\].

We observed a more than 75% higher risk of pancreatic cancer in both men and women with T2DM. A meta-analysis by Song et al., 2015, found that long diabetes duration was associated with a 1.5- to 1.7-fold increased risk of pancreatic cancer \[[@B14-ijerph-17-00246]\]. Although reverse causality has been suspected, constant elevated risk of pancreatic cancer after longer periods of follow-up demonstrate that this is doubtful \[[@B6-ijerph-17-00246],[@B14-ijerph-17-00246]\].

We found a 40% increased risk of kidney cancer in both women and men. This finding is similar to a meta-analysis by Bao et al., 2013, which showed a slightly stronger positive relation in women (RR 1.47, 95% CI 1.18--1.83) than in men (RR 1.28, 95% CI 1.10--1.48) \[[@B15-ijerph-17-00246]\]. Analyses indicate that the increased risk of kidney cancer is independent of alcohol consumption, BMI, obesity, and smoking \[[@B15-ijerph-17-00246]\].

In our study, women with T2DM had a 40% and men had an 80% higher risk for thyroid cancer, although it remained a rare form of cancer in men. The results on thyroid cancer are inconsistent among studies. Our results for women are comparable with a 2014 meta-analysis by Yeo et al., which showed a 30% increased risk in women, but not in men. The risk was higher among women living in areas where thyroid cancer is more common relative to other geographic areas \[[@B16-ijerph-17-00246]\]. However, a later prospective study by Luo et al. \[[@B23-ijerph-17-00246]\] performed in the US of 147 thousand postmenopausal women showed no significant association between diabetes and thyroid cancer, even when diabetes treatment and duration was taken into account \[[@B23-ijerph-17-00246]\]. We hypothesize that the higher estimates for thyroid cancer, especially among men, similarly to increasing rates of thyroid cancer in the whole population, can be explained by the fact that diabetic patients in Lithuania usually undergo thyroid ultrasound scanning routinely, and ultrasound guided fine needle biopsy if needed, therefore even micro-carcinomas can be detected early \[[@B24-ijerph-17-00246]\].

Our study showed a 23% increased colorectal cancer risk in men. Several meta-analyses of cohort and case-control studies demonstrated an increased risk of colorectal cancer in both women and men with diabetes \[[@B17-ijerph-17-00246],[@B18-ijerph-17-00246],[@B19-ijerph-17-00246]\]. A latest meta-analysis of 38 cohort studies suggested that there was no evidence of a sex difference for colorectal cancer among patients with diabetes compared to those without diabetes (ratio of RR 0.99, 95% CI 0.94--1.04) \[[@B18-ijerph-17-00246]\]. T2DM and colon cancer share common risk factors such as obesity and smoking, but even when adjusted for these factors, the positive association remains \[[@B19-ijerph-17-00246]\].

Some significant associations were sex-specific. Women with diabetes had a two-fold increased risk of corpus uteri cancer, which is a well-recognized association and our results are comparable to the latest meta-analyses \[[@B20-ijerph-17-00246],[@B21-ijerph-17-00246]\]. Our study showed a significantly higher risk for breast cancer, which is comparable with a meta-analysis by Liao et al., 2011, according to which, the association between diabetes and breast cancer was the most obvious in Europe (RR 1.88, 95% CI 1.56--2.25), followed by America (RR 1.16, 95% CI 1.12--1.20), but it was not significant in Asia (RR 1.01, 95% CI 0.84--1.21) \[[@B22-ijerph-17-00246]\].

There was no reduction in prostate cancer risk among men with T2DM in our study, in contrast to a recent meta-analysis, which showed a decreased risk of prostate cancer in diabetic men (RR 0.86, 95% CI 0.80--0.92) \[[@B25-ijerph-17-00246]\]. In Lithuania an official nationwide prostate cancer early detection program was introduced in 2006, resulting in subsequent prostate cancer incidence peaks \[[@B26-ijerph-17-00246]\]. Therefore, obtained risk excess of prostate cancer in our study group could in part be explained by surveillance bias since patients with diabetes are under increased surveillance and are more likely to undergo additional medical examinations including prostate-specific antigen (PSA) testing. The use of PSA testing as an early detection tool may cause overdiagnosis or detection of indolent tumors \[[@B27-ijerph-17-00246]\].

We found a lower risk of lung, tracheal, oesophageal, mouth, and laryngeal cancer in diabetic men. In comparison, a meta-analysis of 13 studies indicates that DM is positively correlated with oesophageal cancer, although there were limitations on potential clinical confounding factors in each study included in the meta-analysis \[[@B28-ijerph-17-00246]\]. Cancers of the oral cavity, pharynx, oesophagus, and larynx, together with cancers of the trachea and lungs, are commonly associated with smoking and alcohol use \[[@B29-ijerph-17-00246]\]. Lower risk of some cancers in our study may be explained by a different distribution of well-known risk factors in diabetic patients compared to the general population.

Our study has strengths and limitations. The strengths of this study are the evaluation based on real life data from two well established registries. This study is population based with a large sample size, long follow-up time, and the diagnosis of T2DM is well defined. We add more precise risk estimates for some of the less common cancers to the current literature on T2DM and cancer incidence.

The limitations of our study are those typical in observational studies, such as lack of confounding factors and the potential interactions of diabetes and cancer, for example, problems involving reverse causality, common risk factors and competing risks. It is possible that we have underestimated the impact since standard for calculation of SIR was given by the whole population, which may also include undiagnosed T2DM patients or those treated outside the national health insurance scheme.

5. Conclusions {#sec5-ijerph-17-00246}
==============

In conclusion, our study shows a heightened risk of overall cancer in women and several types of site-specific cancer in patients with T2DM in Lithuania. Significantly increased risk was found for cancers of the liver, pancreas, kidney and thyroid in both men and women. Risk of colorectal cancer, skin melanoma, and non--melanoma skin cancer was elevated among males, and risk of breast and corpus uteri cancers among females.
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###### 

Characteristics of the study population.

  Characteristic                         Males (48,467)   Females (78,823)   Total (127,290)
  -------------------------------------- ---------------- ------------------ -----------------
  Mean age at study entry, y (SD)        59.7 (10.4)      64.0 (10.6)        62.4 (10.7)
  40--49 y, No. (%)                      9639 (20)        7971 (10)          17,610 (14)
  50--59 y, No. (%)                      15,808 (32)      20,617 (26)        36,425 (29)
  60--69 y, No. (%)                      14,371 (30)      26,254 (33)        40,625 (32)
  70+                                    8649 (18)        23,981 (31)        32,630 (25)
  Mean duration of follow-up, y (SD)     6.1 (3.9)        6.8 (4.0)          6.5 (3.9)
  Total No. of person-years at risk      295,390          532,852            828,242
  No. of cancer cases                    5959             6661               12620
  Mean age at cancer diagnosis, y (SD)   69.0 (8.8)       70.4 (9.4)         69.7 (9.1)

SD, standard deviation.
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###### 

Observed and expected numbers of cancer cases and standardized incidence ratios with 95% confidence intervals among Lithuanian type 2 diabetic patients during 2000--2012 by site according to the International Classification of Diseases Australian Modification.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Primary Site                                                                               ICD\                      Males   Females                                            
                                                                                             10-AM Code                                                                           
  ------------------------------------------------------------------------------------------ ------------------------- ------- --------- ------ ------------ ------ ------ ------ ------------
  All Sites                                                                                  C00--C96                  5959    5934      1.00   0.98--1.03   6661   5724   1.16   1.14--1.19

  Lip                                                                                        C00                       21      23        0.93   0.61--1.43   9      11     0.79   0.41-1.52

  Mouth and pharynx                                                                          C01--C14                  73      149       0.49   0.39--0.62   32     40     0.81   0.57--1.14

  Oesophagus                                                                                 C15                       46      93        0.50   0.37--0.66   16     20     0.79   0.49--1.29

  Stomach                                                                                    C16                       325     339       0.96   0.86--1.07   303    305    0.99   0.89--1.11

  Colon, rectum, rectosigmoid, anus                                                          C19--C21                  627     508       1.23   1.14--1.33   682    640    1.07   0.99--1.15

  Liver                                                                                      C22                       139     66        2.11   1.79--2.49   86     59     1.45   1.17--1.79

  Gallbladder, bile ducts                                                                    C23, C24                  28      24        1.17   0.81--1.70   66     63     1.05   0.82--1.33

  Pancreas                                                                                   C25                       265     150       1.77   1.57--1.99   325    187    1.74   1.5--61.93

  Other digestive organs                                                                     C17, C26, C48             15      17        0.89   0.54--1.47   42     29     1.45   1.07--1.97

  Nasal cavity, middle ear, accessory sinuses                                                C30, C31                  7       10        0.68   0.32--1.42   6      8      0.76   0.34--1.69

  Larynx                                                                                     C32                       63      111       0.57   0.44--0.73   6      7      0.83   0.37--1.85

  Lung, trachea                                                                              C33, C34                  436     828       0.53   0.48--0.58   183    211    0.87   0.75--1.00

  Other respiratory tract                                                                    C37--C39                  4       6         0.62   0.23--1.64   5      5      0.99   0.41--2.37

  Bone and connective tissue                                                                 C40, C41, C45--C47, C49   28      29        0.98   0.68--1.42   33     36     0.91   0.65--1.28

  Skin, melanoma                                                                             C43                       72      52        1.40   1.11--1.76   101    111    0.91   0.75--1.10

  Skin, non-melanoma                                                                         C44                       566     498       1.14   1.05--1.23   1033   1049   0.98   0.93--1.05

  Breast                                                                                     C50                       10      9         1.17   0.63--2.17   1114   900    1.24   1.17--1.31

  Vulva                                                                                      C51                       \-      \-        \-     \-           53     45     1.17   0.89--1.53

  Cervix uteri                                                                               C53                       \-      \-        \-     \-           198    212    0.93   0.81--1.07

  Corpus uteri                                                                               C54, C55                  \-      \-        \-     \-           872    422    2.07   1.93--2.21

  Ovary                                                                                      C56                       \-      \-        \-     \-           249    264    0.94   0.83--1.07

  Other female genital organs                                                                C52, C57--C58             \-      \-        \-     \-           13     17     0.76   0.44--1.31

  Male genital organs                                                                        C60, C63                  27      15        1.86   1.27--2.71   \-     \-     \-     \-

  Prostate                                                                                   C61                       2164    2074      1.04   1.00--1.09   \-     \-     \-     \-

  Testis                                                                                     C62                       4       4         1.04   0.39--2.78   \-     \-     \-     \-

  Kidney                                                                                     C64                       336     231       1.46   1.31--1.62   312    218    1.43   1.28--1.60

  Urinary bladder                                                                            C67                       214     208       1.03   0.90--1.18   97     86     1.13   0.93--1.38

  Other urinary tract                                                                        C65, C66, C68             10      10        0.99   0.53--1.84   13     11     1.19   0.69--2.05

  Eye and adnexa                                                                             C69                       8       7         1.13   0.56--2.26   12     13     0.95   0.54--1.68

  Central nervous system                                                                     C70--C72                  46      61        0.76   0.57--1.01   88     90     0.98   0.79--1.21

  Thyroid                                                                                    C73                       36      20        1.83   1.32--2.54   196    140    1.40   1.22--1.62

  Other endocrine organs                                                                     C74, C75                  10      5         1.96   1.05--3.64   9      7      1.36   0.71--2.62

  Other and ill-defined sites                                                                C76--C80                  138     130       1.06   0.90--1.25   173    147    1.18   1.01--1.37

  Non-Hodgkin lymphoma                                                                       C81                       5       6         0.78   0.32--1.87   7      8      0.84   0.40--1.77

  Hodgkin lymphoma                                                                           C82--C85                  72      82        0.87   0.69--1.10   145    130    1.12   0.95--1.31

  Myeloma                                                                                    C90                       40      40        0.99   0.73--1.35   55     75     0.74   0.57--0.96

  Leukaemia                                                                                  C91--C95                  123     127       0.97   0.81--1.16   126    155    0.81   0.68--0.97

  Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue   C88, C96                  1       4         0.26   0.04--1.87   1      4      0.25   0.04--1.80
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Obs, observed; Exp, expected; SIR, standardized incidence ratios; CI, confidence interval; ICD10-AM, International Classification of Diseases Australian Modification.
